Death followed HPV vaccine in UK: statement by GSK

A fatality has been reported in the UK HPV vaccine immunisation programme, and pharma giant GSK has issued a statement.
GSK makes the cervical cancer vaccine Cervarix, which is used in the programme. IMT understands that the girl, a 14-year-old, died one hour after receiving the vaccine.
The press release:
GSK was notified by the UK’s Department of Health on Monday 28th September of the death of a 14 year old girl who was vaccinated with GSK’s cervical cancer vaccine, Cervarix, as part of the national HPV immunisation programme.
Dr Pim Kon, Medical Director, GlaxoSmithKline UK said: “Our deepest sympathies are with the family and friends of the young girl.
“We are working with the Department of Health and MHRA to better understand this case, as at this stage the exact cause of this tragic death is unknown. As a precautionary measure, the batch of vaccine involved has been quarantined until the situation is fully understood.”
More than 1.4 million doses of Cervarix have been given as part of the national immunisation programme in the UK.
To date the vast majority of suspected adverse reactions reported to the MHRA in association with Cervarix vaccine have related either to the signs and symptoms of recognised side effects listed in the product information or were due to the injection process and not the vaccine itself.